Evidence map›Paper›PMID 42740439›Full record

ArticleGut and liver2026

Differential Cancer Risks and Noninvasive Predictors in MASLD, MetALD, and ALD: A Longitudinal Analysis.

Hana Park, Ji Young Lee, Ja Eun Koo, Jong Soo Lee, Sungwon Park, Hye Won Park, Hye-Sook Chang, Hong-Kyu Kim, Jaewon Choe, Ju Hyun Shim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hana ParkDepartment of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8449-034X
Ji Young LeeDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0764-615X
Ja Eun KooDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2276-4779
Jong Soo LeeDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8002-2693
Sungwon ParkDivision of Radiology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7032-8496
Hye Won ParkDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-1320-0557
Hye-Sook ChangDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3095-7164
Hong-Kyu KimDivision of Endocrinology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7606-3521
Jaewon ChoeDivision of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0393-6803
Ju Hyun ShimDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-7336-1371

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: The recently proposed classification of steatotic liver disease (SLD) comprises metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD). Long-term cancer risk across these phenotypes remains incompletely characterized, and was investigated in this study. Methods: This longitudinal cohort study included 43,994 adults who underwent health check-ups in 2010-2011. Liver steatosis was diagnosed by ultrasonography. The Fibrosis-4 (FIB-4) and steatosis-associated fibrosis estimator (SAFE) scores were evaluated as predictors of cancer incidence. Results: Over a median 10.5 years (398,202 person-years), 3,169 cancers occurred (795.8 per 100,000 person-years). Versus no SLD, overall cancer risk was elevated in ALD (incidence rate ratio [IRR], 1.38; 95% confidence interval, 1.08 to 1.79) but not MASLD or MetALD. Hepatocellular carcinoma risk increased across all SLD groups, most strongly in the MetALD and ALD groups, with a more modest association in the MASLD group that was attenuated in sensitivity analyses. ALD was associated with an elevated risk of esophageal cancer (IRR, 5.98) and stomach cancer (IRR, 2.41), and MetALD with an increased risk of stomach cancer (IRR, 1.61). FIB-4 and SAFE showed dose-response associations with cancer that were substantially attenuated after age adjustment, persisting mainly at the highest categories. Conclusions: Cancer risk differs across MASLD, MetALD, and ALD, with alcohol-related phenotypes carrying the highest burden. Noninvasive fibrosis indices such as FIB-4 and SAFE may help stratify risk-though largely age-related-and could inform risk-based surveillance in SLD.

Indexed as

Alcohol DrinkingFatty LiverLiver Diseases, AlcoholicNeoplasmsAdultAgedCarcinoma, HepatocellularEsophageal NeoplasmsFemaleHumansIncidenceLiver NeoplasmsLongitudinal StudiesMaleMiddle AgedRisk FactorsAlcoholAlcohol drinkingFatty liverLiver diseasesNeoplasms

Identifiers

PMID42740439
PMCPMC13575830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.